Amy K Goodwin1, K Michael Gibson, Elise M Weerts. 1. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, USA. Electronic address: Goodwin@jhu.edu.
Abstract
BACKGROUND: 1,4-Butanediol (1,4-BD) is a gamma-hydroxybutyrate (GHB) pro-drug, with multiple commercial uses, and a drug of abuse. Although there are case reports of a withdrawal syndrome following 1,4-BD use, no studies have evaluated the physical dependence potential of 1,4-BD and characterized the time course of withdrawal. METHODS: Vehicle and then 1,4-BD were administered continuously 24 h/day via intragastric catheters in male baboons (Papio anubis, n=3). Dosing was initiated at 100 mg/kg and increased by 100mg/kg/day to 400mg/kg. After a stabilization period, doses of 500 and then 600 mg/kg/day were each maintained for 3-4 weeks. Plasma levels of 1,4-BD and GHB were determined for each dose condition. Physical dependence was assessed via administration of a GABA-B antagonist (precipitated withdrawal test) during administration of the 600 mg/kg dose and via abrupt termination of chronic 1,4-BD administration (spontaneous withdrawal test). Outcome measures included the number of food pellets earned, performance on a fine-motor task, observed behaviors, and plasma levels of GHB and 1,4-BD. RESULTS: Following maintenance of 1,4-BD 600 mg/kg for 3 weeks, the number of food pellets earned was significantly decreased. At the end of chronic 1,4-BD dosing, the levels of GHB in plasma ranged from 1290 to 2300 μmol/L and levels of 1,4-BD in plasma ranged from 13.1 to 37.9 μmol/L. Signs of physical dependence were observed following precipitated and spontaneous withdrawal tests. Seizures were not observed. CONCLUSIONS: These data indicate chronic 1,4-BD produced physical dependence in baboons and the withdrawal syndrome can be characterized as mild to intermediate.
BACKGROUND:1,4-Butanediol (1,4-BD) is a gamma-hydroxybutyrate (GHB) pro-drug, with multiple commercial uses, and a drug of abuse. Although there are case reports of a withdrawal syndrome following 1,4-BD use, no studies have evaluated the physical dependence potential of 1,4-BD and characterized the time course of withdrawal. METHODS: Vehicle and then 1,4-BD were administered continuously 24 h/day via intragastric catheters in male baboons (Papio anubis, n=3). Dosing was initiated at 100 mg/kg and increased by 100mg/kg/day to 400mg/kg. After a stabilization period, doses of 500 and then 600 mg/kg/day were each maintained for 3-4 weeks. Plasma levels of 1,4-BD and GHB were determined for each dose condition. Physical dependence was assessed via administration of a GABA-B antagonist (precipitated withdrawal test) during administration of the 600 mg/kg dose and via abrupt termination of chronic 1,4-BD administration (spontaneous withdrawal test). Outcome measures included the number of food pellets earned, performance on a fine-motor task, observed behaviors, and plasma levels of GHB and 1,4-BD. RESULTS: Following maintenance of 1,4-BD 600 mg/kg for 3 weeks, the number of food pellets earned was significantly decreased. At the end of chronic 1,4-BD dosing, the levels of GHB in plasma ranged from 1290 to 2300 μmol/L and levels of 1,4-BD in plasma ranged from 13.1 to 37.9 μmol/L. Signs of physical dependence were observed following precipitated and spontaneous withdrawal tests. Seizures were not observed. CONCLUSIONS: These data indicate chronic 1,4-BD produced physical dependence in baboons and the withdrawal syndrome can be characterized as mild to intermediate.
Authors: Lance R McMahon; Andrew Coop; Charles P France; Gail Winger; William L Woolverton Journal: Eur J Pharmacol Date: 2003-04-11 Impact factor: 4.432
Authors: Amy K Goodwin; Roland R Griffiths; P Rand Brown; Wolfgang Froestl; Cornelis Jakobs; K Michael Gibson; Elise M Weerts Journal: Psychopharmacology (Berl) Date: 2006-09-20 Impact factor: 4.530
Authors: Mauro A M Carai; Lawrence S Quang; Sergio Atzeri; Carla Lobina; Paola Maccioni; Alessandro Orrù; Gian Luigi Gessa; Timothy J Maher; Giancarlo Colombo Journal: Brain Res Brain Res Protoc Date: 2005-07
Authors: Christopher M de Fiebre; Nancy Ellen C de Fiebre; Scott L Coleman; Michael J Forster Journal: Pharmacol Biochem Behav Date: 2004-04 Impact factor: 3.533
Authors: Victor R Santos; Ihori Kobayashi; Robert Hammack; Gregory Danko; Patrick A Forcelli Journal: Epilepsy Res Date: 2018-09-18 Impact factor: 3.045
Authors: Iram P Rodriguez-Sanchez; Josee Guindon; Marco Ruiz; M Elizabeth Tejero; Gene Hubbard; Laura E Martinez-de-Villarreal; Hugo A Barrera-Saldaña; Edward J Dick; Anthony G Comuzzie; Natalia E Schlabritz-Loutsevitch Journal: Neurotoxicol Teratol Date: 2016-06-18 Impact factor: 3.763